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Transfection of chimeric chloramphenicol acetyltransferase plasmids containing various deletions of the human gastric inhibitory polypeptide (GIP) 
promoter into hamster insulinoma (HIT T15) cells indicated that the region between -180 and + I4 is sufficient for basal promoter activity. Two 
CRE-BP1 binding sites were identified in this promoter egion by DNase I footprinting with the bacterially expressed CAMP response lement (CRE) 
binding protein, CRE-BPl. Mutation analyses howed that these two CREs are required for the basal promoter activity, and furthermore that 
one site, at nucleotide-158, contributed mainly to the CAMP inducibility of the GIP promoter in HIT T15 cells. Interestingly, the GIP promoter 
activity was repressed by the c-jun proto-oncogene product, possibly through the CREs. 
Gastric inhibitory protein; CAMP response element; Glucose; Jun 
1. INTRODUCTION 
Gastric inhibitory polypeptide (GIP) was first re- 
ferred to as enterogastrone [l], since it was purified from 
porcine intestinal extracts on the basis of its ability to 
inhibit gastric acid secretion [2,3]. However, subsequent 
studies on GIPs biological role indicated that the major 
action of this peptide is to stimulate insulin secretion at 
elevated glucose levels [4,5], rather than to inhibit gas- 
tric acid secretion [6]. GIP consists of 42 amino acid 
residues [7], and is a member of the glucagon-secretin 
family, which also contains vasoactive intestinal peptide 
and growth hormone-releasing factor [S-lo]. 
Analysis of the human GIP cDNA showed that GIP 
is derived by proteolytic processing of a 153 amino acid 
precursor [ll]. The human gene coding for the GIP 
precursor contains six exons and was assigned to chro- 
mosome 17q21.3322 [12]. The promoter region of the 
human GIP gene contains potential binding sites for 
multiple transcription factors, including Spl and AP-1, 
but the roles of these sites are unknown [12]. 
GIP could act in maintaining glucose homeostasis by 
functioning as a glucose-dependent insulin-releasing 
peptide. In the regulation of glucose homeostasis, insu- 
lin has a major physiological role, and its own biosyn- 
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thesis is regulated by blood glucose at the transcrip- 
tional [ 13,141 and translational [15] levels. Although the 
mechanism of glucose-induced insulin gene expression 
is poorly understood, the following facts support the 
possibility that CAMP may participate: glucose in- 
creases the CAMP concentration in pancreatic /I cells 
[ 161, and analogues of CAMP augment insulin mRNA 
levels in isolated islets [17]. Since GIP could be also 
important for glucose homeostasis, it is interesting to 
know whether the GIP gene expression is also regulated 
by CAMP and glucose. 
We have demonstrated that CAMP inducibility of 
the human insulin gene transcription is controlled by 
four CAMP response elements (CRE: TGACGTCA) 
[18]. CRE is an inducible enhancer of genes which can 
be transcribed in response to increased CAMP levels 
[ 19,201. Four CREs contributed additively to the CAMP 
inducibility of the insulin promoter. Although multiple 
CRE binding proteins, including CREB 121,221, CRE- 
BP1 [23], and ATFs [24], all of which have the so-called 
‘B-ZIP’ structure, were identified by cDNA cloning, 
only CREB was so far demonstrated to be involved 
in the CAMP-induced transcriptional activation. The 
trans-activating capacity of CREB is activated by phos- 
phorylation of Ser- 133 by CAMP-dependent protein ki- 
nase A [25]. CRE binding proteins bind to CRE as a 
homodimer or heterodimer with other protein, and 
CRE-BP1 can dimerize with the c-jun protooncogene 
product (c-Jun) [26,27]. Interestingly, cJun represses 
the CAMP-induced activity of the insulin promoter [18]. 
Since the CRE-BP1 homodimer, but not the CRE-BPl/ 
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Fig. 1. Deletion analysis of the human GIP gene promoter. (A) Struc- 
ture of the 5’ deletion mutants of the human GIP gene promoter. 
Deletions were generated using the restriction enzyme sites indicated 
above. (B) CAT activities of the 5’ deletion mutants. A mixture of 16 
,ug of each CAT plasmid and 4 pg of the internal control plasmid 
pact-p-gal was transfected into HIT cells, and CAT activity expressed 
in a transient assay was measured. Some cell samples were treated with 
Bt,cAMP as indicated. (C) CAT activity obtained with each CAT 
plasmid is indicated relative to that with pHGCAT-386 without 
Bt,cAMP treatment. 
c-Jun heterodimer, binds to the CREs of the human 
insulin gene, a possibility is that c-Jun inhibits the bind- 
ing of some CRE binding proteins, such as CRE-BPl, 
to the CREs of the insulin gene by formation of a heter- 
odimer. These results, and another observation that the 
level of cJun is dramatically increased by glucose depri- 
vation in hamster insulinoma (HIT T15) cells [18], sug- 
gest that glucose may regulate expression of the human 
insulin gene through CREs and cJun. 
In this study, we have examined the regulation of GIP 
promoter activity by CAMP or c-Jun. We have identi- 
fied two CRE-BP1 -binding sites in the human GIP pro- 
moter and found that one of them is mainly responsible 
for CAMP inducibility. We have also found that the GIP 
promoter activity is also repressed by cJun like the 
human insulin promoter. 
2. MATERIALS AND METHODS 
2.1. Plamid construction 
A series of chloramphenicol acetyltransferase (CAT) plasmids 
shown in Fig. 1A were generated by inserting various lengths of DNA 
fragments containing the human GIP promoter into the Hind111 site 
of pSVOOCAT [28] using a Hind111 linker, To generate the plasmids 
containing the mutated CREl and CRE2 shown in Fig. 4A, oligonu- 
cleotide-directed mutagenesis was done as described by Sayers et al. 
[29]. The CRE-BP1 expression plasmid, pact-CRE-BP1 [30], and the 
cJun expression plasmid, pRSV-c-&n [31], were previously described. 
The plasmid, pGEX-CRE-BPI, to express the glutathione S-trans- 
ferase (GST)-CRE-BP1 fusion protein in bacteria, was constructed as 
follows. A BarnHI site was introduced in front of the translational 
initiation codon of the CRE-BPI gene. Then, the BarnHI-Bg/II DNA 
fragment containing the whole protein-coding region of CRE-BPI 
gene was isolated and cloned into the BumHI site of the pGEX-3X 
vector (Pharmacia). 
2.2. DNA transfecrion and CAT assay 
CAT transfection experiments using HIT cells were done as de- 
scribed [l8]. To examine the basal promoter activity and the CAMP 
inducibility, mixtures of 16,~g of each CAT plasmid DNA, 4pg of the 
internal control plasmid, pact-/?-gal [30], in which the 5 regulatory 
region of the chicken /Lactin gene was linked to the B-galactosidase 
gene, were transfected. To examine the effect of CRE-BPI and c-Jun 
on the GIP promoter activity, two types of conditions were used. In 
the experiments hown in Fig. 5, mixtures of 6 pg of pHGCAT-386 
DNA, various amounts of pact-CRE-BPI, pRSV-c-&z, or the control 
effector plasmid lacking the cDNA sequence to be expressed (total 
amount of the effector plasmid DNA was adjusted to 4,~g by varying 
the amount of the control effector plasmid), and 6 pg of the internal 
plasmid pras-p-gal were transfected. In pras-b-gal [32], the human 
c-Ha-ras-1 promoter [33] was linked to theb-galactosidase g ne. In the 
experiments hown in Fig. 6, mixtures of 12 fig of each CAT plasmid 
DNA, 4 pug of pRSV-c;iun, and 4 pg of pact-p-gal were transfected. 
We had confirmed that the activity of the chicken /?-actin promoter 
or the human c-Ha-ras-1 promoter was not affected by CRE-BP1 or 
c-Jun ([33], our unpublished results). 48 h after transfection, CAT 
activities were measured by the procedure of Gorman et al. [34]. 
The amount of cell extracts used for CAT assays was normalized 
with respect to /&galactosidase activity. The radioactivity of either 
[‘4C]chloramphenicol or its acetylated form was measured by using a 
bioimage analyzer (Fuji). All CAT transfection experiments were re- 
peaked three or four times, and typical results are shown here. The 
differences between each set of experiments were within 20%. 
2.3. Preparation of GST-CRE-BP1 fusion protein 
GST-CRE-BP1 fusion protein expression and purification were es- 
sentially as described by Smith and Johnson [35]. E. coli SG12036 
harboring pGEX-CRE-BP1 was grown at 37°C in 2x YT medium 
containing 50,@ml ampicillin. After this reached an absorption at 550 
nm of 0.6, isopropyl-B-o-thiogalactopyranoside (IPTG) was added 
(final concentration 1 mM) and the bacterial growth was continued 
for 2 h at 37°C. The bacteria were lysed by mild sonication and the 
crude extracts (IO ml) prepared from 500 ml culture were rocked for 
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Fig. 2. Identification of CRE-BP1 binding sites in the promoter region 
of human GIP gene. (A) Purification of the bacterially expressed 
GST-CRE-BPI. The purified GST-CRE-BP1 fusion protein was sep- 
arated on a 10% SDS-polyacrylamide gel and stained with Coomassie 
brilliant blue. (B) Gel mobility shift assay. Four DNA fragments, 
indicated above, were end-labeled and used as probes (probe 14). 
Each probe was incubated with various amounts of the purified GST- 
CRE-BP1 (30 m&l) as indicated, and electrophoresis was in 4% 
polyacrylamide gels of low ionic strength. (C) DNase I footprinting. 
The HindI&KpnI (nucleotides -386 to -209) fragment of pHGCAT- 
386 (lanes l-5). or the BumHI-Hind111 (nucleotides -212 to +14) 
fragment of pHGCAT-I80 (lanes 610) was “P-labeled, incubated 
with 8 .ug of GST-CRE-BP1 (lanes marked +) or without protein 
(lanes marked -), and digested with 10 (lanes marked +), 20 (lanes 
marked ++), or 40 (lanes marked +++) &ml DNase I. Markers 
(lanes marked G) were obtained by the chemical cleavage of the same 
end-labeled DNA fragment. The protected regions are depicted on the 
right. Nucleotide sequences of two sites protected by GST-CRE-BP1 
are shown below. 
60 min at 4°C with 3 ml of glutathione-Sepharose beads in phosphate- 
buffered saline (PBS). The beads were washed with PBS, and the 
GST-CRE-BP1 fusion protein was then eluted with elution buffer (5 
mM glutathione, 50 mM Tris-HCI, pH 8.0). 
2.4. Gel mobility shif assay and DNase Ifootprinting 
For gel mobility shift assay, variable amounts of purified GST- 
CRE-BP1 fusion proteins were incubated for I5 min at 25°C with 1 
ng of “P-labeled DNA fragment in 15 ,uI of binding buffer (6.7 mM 
Tris-HC1, pH 7.5.3.3 mM sodium acetate, 1 mM EDTA, 5% glycerol). 
The reaction mixtur.: was then put onto a 4% polyacrylamide gel in 
0.25x TBE (22.25 mM Trizma base, 22.25 mM boric acid, 0.5 mM 
EDTA) and electrophoresed. For DNase I footprint experiments, 
DNA binding reactions and DNase I digestions were done in a 6O;ul 
volume with 335 ng (about l&20 fmol) of an end-labeled DNA frag- 
ment and various amounts of purified GST-CRE-BPl, in the same 
buffer as that for the gel retardation assay. Reactions were incubated 
for 30 min at 25°C and then digested for 60 s at 20°C with 8 ~1 of 
freshly diluted IO&400 &ml solution of DNase I after addition of 
MgClz to a final concentration of 10 mM. 
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3. RESULTS 
3.1. Deletion analysis of the human GIP gene promoter 
To examine the promoter activity of the region up- 
stream from the RNA start site which was previously 
reported [12], the 1.2-kbp AvaII DNA fragment (nu- 
cleotides +14 to -1,200) was placed on the 5’ side of 
the bacterial CAT gene derived from the plasmid, 
pSVOOCAT [28]. The ability of this construct 
(pHGCAT-1200) to express CAT activity was tested by 
transfection of DNA into HIT cells. After 48 h, the 
significant level of CAT activity was observed, and the 
level of CAT activity was increased about 5-fold by 
treatment with N6,02-dibutyryladenosine 3’,5’-cyclic 
monophosphate (B&AMP) (Fig. lB, lanes 1 and 2) 
indicating that the 1.2-kbp AvaII fragment has a pro- 
moter activity that is regulated by CAMP. To identify 
the region required for GIP promoter activity, a series 
of deletion fragments of the GIP gene promoter were 
ligated 5’ to the CAT gene and tested for promoter 
activity. The structures of the various deletions and 
their relative promoter activities in the presence or ab- 
sence of Bt,cAMP are shown in Fig. 1. Deletions from 
the 5’ end of the insert to nucleotides -386 (pHGCA- 
386) or -334 (pHGCAT-334) resulted in a 40% or 70% 
decrease in the basal promoter activity. Further dele- 
tions to nucleotides -258 (pHGCAT-258) or -180 
(pHGCAT-1 SO) increased the basal promoter activity 
to the level of 57% or 150% of that of pHGCAT-1200. 
These results suggest the presence of both positive and 
negative elements in the region between nucleotides 
- 1,200 and - 180. Furthermore, with these four deletion 
mutants, the CAMP inducibility was still observed. 
However, deletion to nucleotides -134 almost com- 
pletely abolished both the basal promoter activity and 
the CAMP inducibility. These results indicate that the 
region between nucleotides - 180 and - 134 contains the 
cis element responsible for the CAMP-induced trans- 
activation and basal promoter activity. 
3.2. Ident@ication of two CREs 
To identify the CRE within the human GIP promoter 
region, we next did a mobility shift assay and DNase I 
footprinting using the bacterially synthesized fusion 
proteins (GST-CRE-BPl) between glutathione S-trans- 
ferase and the CRE binding protein, CRE-BPl. Four 
DNA fragments covering the region between nucleo- 
tides -386 and +14 of the human GIP gene were pre- 
pared and used as a DNA probe for a gel mobility shift 
assay. The GST-CRE-BP1 proteins bound to all four 
32P-labeled probe and generated protein-DNA com- 
plexes (Fig. 2A), indicating that multiple CRE-BPl- 
binding sites are localized in the GIP promoter region. 
In DNase I footprint assay, GST-CRE-BP1 protected 
two regions: CREl at nucleotides -350 to -339 and 
CRE2 at nucleotides -164 to -149 (Fig. 2B). We ob- 
served that these two regions were also protected in 
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Fig. 3. Effects of mutation of the CRE-BPl-binding sites on the CAMP 
inducibility of GIP gene promoter. (A) Mutations introduced into the 
CRE-BPl-binding sites of the GIP promoter region. The wild-type 
sequences of two CRE-BPl-binding sites are shown at the top. The 
nucleotide sequences of the consensus CRE and each mutant are 
indicated below. (B) Transient expression of CAT activity. CAT co- 
transfection assays were done and the results are presented as in 
Fig. 1. 
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Fig. 4. Repression of promoter activity of the human GIP gene by cJun. pHGCAT-386 was transfected with 1,2, or 4 pg of the CRE-BP1 expression 
plasmid (lanes 24), with 1, 2, or 4 pg of the c&n expression plasmid (lanes 5-7), or with the control effector plasmid (lane 1) into HIT cells, and 
CAT activities were measured. Relative CAT activities are indicated by a bar graph on the right. 
DNase I footprinting using HIT cells nuclear extract 
(data not shown). Within the core of CREl-protect- 
ed region, the CRE-like sequence is localized 
@GACGTGA: the underlined residues are different 
from the consensus CRE). However, the nucleotide se- 
quence in the CREZprotected region had no striking 
homology with the consensus CRE sequence, and this 
region contains the CCAAT box. 
3.3. Role of CREs in the GIP gene transcription 
To examine whether the two CRE-BP1 binding sites 
confer the CAMP inducibility on the human GIP gene, 
mutant pHGCAT plasmids containing mutated CREs 
were constructed and used for CAT transfection assays. 
The CAT activities expressed in HIT cells by the wild- 
type and mutant plasmids are shown in Fig. 3B. The 
level of CAT activity expressed from the control plas- 
mid, pHGCAT-386, was increased about 4.5-fold by 
treatment with Bt,cAMP. When CREl was disrupted 
(m21), the degree of induction by Bt,cAMP was slightly 
reduced to a 3-fold increase. Although the CRE-like 
sequence was not found in the CRE2 site, the sequence 
TCAC in the 5’ half of the center of the protected region 
is similar to the sequence TGAC of the half sequence 
of consensus CRE (TGACGTCA). To examine whether 
this TCAC sequence is important for the CAMP-in- 
duced activation of the GIP promoter, this TCAC se- 
quence was changed to AGCC (m22). This mutation 
almost completely abolished the CAMP inducibility of 
the GIP promoter. To confirm further that the presence 
of a half sequence (TGAC) of the consensus CRE at this 
position is sufficient for CAMP inducibility, a one- 
base mutation was introduced to generate the sequence 
TGAC (m23). As expected, a generation of the sequence 
TGAC increased the CAMP inducibility to ‘I-fold. Intro- 
duction of the 3-base mutation (m19) in the center of the 
protected region also dramatically reduced the CAMP 
inducibility to 2-fold. Disruption of both the CREl and 
CRE2 sites (m21/22 produced by combination of m21 
and m22) gave a result similar to that obtained with 
m22. These results indicate that among two CRE-BPl- 
binding sites, the CRE2 site is mainly responsible for the 
CAMP-induced activation of the GIP promoter. Fur- 
thermore, a combination of the half sequence of consen- 
sus CRE and the CCAAT box sequence gives rise to a 
functional CRE. 
In the CAT assays described above, smaller amount 
of extracts prepared from the transfected cells were used 
for CAT assays to measure the degree of CAMP induc- 
ibility as precisely as possible. Under those conditions, 
however, an accurate comparison of the basal promoter 
activities between the wild-type and mutant promoters 
was difficult. To examine whether mutations of the 
CRE-BP1 -binding sites affect the basal promoter activ- 
ity, CAT activities obtained by more of the cell extracts 
were compared (see the data obtained without a c- 
Jun expression plasmid in Fig. 5). Disruption of CREl 
(m21) and CRE2 (m22 and m19) decreased the basal 
promoter activity to about half and to l/9 to l/7 of 
the wild-type promoter, respectively. Combination of 
CREl and CRE2 mutations (m21/22) suppressed it to 
about l/15. These results show that two CRE-BP1 bind- 
ing sites also contributed to the basal promoter activity. 
3.4. c-Jun-induced repression of the GIP promoter activ- 
ity 
Previously we observed that cJun can repress the 
human insulin promoter activity [18]. Since the level of 
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Fig. 5. Effects of mutation of CRE-BPI-binding sites on the cJun- 
induced repression. A series of CAT plasmids indicated in Fig. 3, were 
co-transfected with the cJun expression plasmid or the control effec- 
tor plasmid into HIT cells, and CAT activities were assayed. Relative 
CAT activities are shown by a bar graph below. 
c-jun mRNA was increased by glucose deprivation in 
HIT cells [18], this observation suggest that glucose may 
regulate the human insulin promoter activity through 
cJun. To examine whether c-Jun also regulated tran- 
scription of the human GIP gene, which is also impor- 
tant for glucose homeostasis, like the insulin gene, the 
CAT co-transfection assays were done. Co-transfection 
of pHGCAT-386 and various amounts of the cJun 
expression plasmid into HIT cells showed that cJun 
represses the basal activity of the GIP promoter to one- 
third to one-fifth (Figs. 4 and 5). In contrast, co-trans- 
fection of the CRE-BP1 expression plasmid did not af- 
fect the basal promoter activity (Fig. 4) suggesting that 
the level of endogenous level of CRE-binding proteins 
in HIT cells is sufficient to maintain the activity of the 
GIP promoter. To investigate whether the two CREs 
mediate the c-Jun-induced repression, the mutants of 
CREs were used for a co-transfection experiment (Fig. 
5). The mutation of CREl (m21) or CRE2 (m22) did 
not affect the repression by cJun, but disruption of 
both CREI and CRE2 (m21/22) partially relieved the 
cJun-induced repression. These results indicate that c- 
Jun represses the basal promoter activity of the human 
GIP gene partly through two CREs. 
4. DISCUSSION 
These studies demonstrate that the human GIP gene 
transcription can be induced by an increased level of 
CAMP. DNase I footprinting with the recombinant 
CRE binding proteins and mutagenesis analysis show 
that two CRE-BP1 binding sites are in the human GIP 
promoter region and that one of them, at nucleotide 
-155, is mainly responsible for the CAMP inducibility 
of the human GIP promoter. In addition, these two sites 
also contribute to the basal activity of the GIP pro- 
moter. Surprisingly, the nucleotide sequence of the 
CRE-BP1 binding site at nucleotide - 155 does not have 
a high homology with the consensus CRE sequence. 
The 5’ half of this site contains the sequence, TCAC, 
which is similar to the 5’ half sequence of the consensus 
CRE (TGACGTCA), and the 3’ half of this site has the 
CCAAT box. The importance of this 5’ half has been 
demonstrated by experiments in which a generation of 
TGAC in this region by introducing a point mutation 
increases the CAMP inducibility (Fig. 3, m23). These 
results suggest that only one molecule of CRE-BP1 ho- 
modimer, which is formed through the leucine zipper, 
may recognize the TCAC sequence of the 5’ half in a 
sequence-specific manner. It is not clear whether an- 
other molecule of CRE-BP1 homodimer can specifically 
recognize the CCAAT sequence. Among multiple pro- 
teins binding to a CCAAT box, C/EBP has the B-ZIP 
structure consisting of the basic amino acid cluster and 
a leucine zipper [36], and was recently demonstrated to 
be able to bind to a CRE sequence [37]. These results 
raise the possibility that a homodimer of CRE binding 
proteins or C/EBP, or a heterodimer of some CRE bind- 
ing protein and CIEBP, binds to the CRE2 site of the 
human GIP gene promoter in vivo, although a heterod- 
imer formation between these two kinds of proteins has 
not been demonstrated. An increase of the CAMP level 
has been shown to stimulate a nuclear localization and 
the transactivation capacity of NFIL-6, one member of 
the C/EBP family [38]. Therefore, it might be possible 
that the NFIL-6-like protein may contribute to the 
CAMP inducibility of the human GIP promoter, if some 
member of C/EBP family binds to the CRE2 site. It is 
quite interesting to examine what kind of transcription 
factor binds to CRE2 in the GIP promoter and regu- 
lates its activity. 
We previously reported that cJun represses the pro- 
moter activity of the human insulin gene through four 
CREs [18]. Our results in this study indicate that the 
human GIP promoter activity can also be repressed by 
cJun, at least partly, through two CREs in HIT cells. 
Since the c-jun mRNA level increases upon glucose dep- 
rivation in HIT cells [18], glucose may induce the GIP 
gene transcription by reducing the level of c-&n mRNA. 
At present, it is not clear whether the GIP gene expres- 
sion is regulated by glucose, because HIT cells have a 
weak responsiveness to glucose at physiological concen- 
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trations. A study using primary j%cells that can respond 
to glucose will be necessary to clarify this point. Al- 
though the mechanism of c-Jun-induced transcriptional 
repression of the insulin and GIP genes is not yet clear, 
the fact that expression of both of two genes, which are 
important for glucose homeostasis, are similarly regu- 
lated, suggests a physiological importance of this type 
of regulation. 
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